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Abstract
Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic
Myelogenous Leukemia (CML) demands new therapeutic strategies. We and others have previously established
bortezomib, a selective proteasome inhibitor, as an important potential treatment in CML. Here we show that the
combined regimens of bortezomib with mitotic inhibitors, such as the microtubule-stabilizing agent Paclitaxel and the
PLK1 inhibitor BI2536, efficiently kill TKIs-resistant and -sensitive Bcr-Abl-positive leukemic cells. Combined
treatment activates caspases 8, 9 and 3, which correlate with caspase-induced PARP cleavage. These effects are
associated with a marked increase in activation of the stress-related MAP kinases p38MAPK and JNK. Interestingly,
combined treatment induces a marked decrease in the total and phosphorylated Bcr-Abl protein levels, and inhibits
signaling pathways downstream of Bcr-Abl: downregulation of STAT3 and STAT5 phosphorylation and/or total levels
and a decrease in phosphorylation of the Bcr-Abl-associated proteins CrkL and Lyn. Moreover, we found that other
mitotic inhibitors (Vincristine and Docetaxel), in combination with bortezomib, also suppress the Bcr-Abl-induced pro-
survival signals and result in caspase 3 activation. These results open novel possibilities for the treatment of Bcr-Abl-
positive leukemias, especially in the imatinib, dasatinib and nilotinib-resistant CML cases.
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Introduction
The t(9:22) chromosomal translocation resulting in the
Philadelphia chromosome leads to the expression of the Bcr-
Abl fusion protein, which plays a critical role in the
pathogenesis and progression of Chronic Myeloid Leukemia
(CML), in a subset of Acute Lymphoblastic Leukemia (Ph+ALL;
15% to 30% cases) and occasionally in Acute Myelogenous
Leukemia (Ph+AML) [1]. Bcr-Abl functions as a constitutively
active kinase, activating critical downstream pathways
implicated in proliferation, survival or cell movement, such as:
Ras-ERK, PI3K-AKT, JAK-STAT or CrkL/Lyn-dependent
pathways [2].
Current inhibitors of Abl kinases, such as imatinib mesylate
(imatinib), dasatinib or nilotinib have shown great potential in
the treatment of CML. However, the emergence of resistance
and residual disease eventually lead to CML progression [3].
Imatinib, dasatinib or nilotinib resistance may emerge through
Bcr-Abl mutations (such as T315I) and/or Bcr-Abl amplification
[4]. Moroever, while a recently approved TKI, Ponatinib, is
effective in patients with T315I mutation, cardiovascular,
cerebrovascular and peripheral vascular thrombosis, including
fatal myocardial infarction and stroke, have occurred in
ponatinib-treated patients [5]. Thus, novel therapeutic
strategies that target both imatinib-, dasatinib- or nilotinib-
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resistant and -sensitive Bcr-Abl-positive leukemias, such as
CML, need to be developed.
We and others have previously shown that bortezomib
(velcade, PS-341), a selective proteasome inhibitor (approved
by European Medicines Agency & US Food and Drug
Administration (FDA) for the treatment of multiple myeloma and
mantle cell lymphoma) efficiently inhibits survival and induces
apoptosis in imatinib-resistant Bcr-Abl cells [1]. Bortezomib
significantly reduces the signs of CML-like disease in Bcr-Abl
transduced mice [1]. Moreover, we also reported that
bortezomib treatment caused remission in a patient with Bcr-
Abl positive Acute Lymphoblastic Leukemia (ALL), refractory to
standard therapies [6]. An excellent response with a complete
remission, maintained for more than 4 years since the patient’s
initial diagnosis and beginning of the treatment was observed
[6]. Based on these results, more than five different clinical
trials have been initiated, using bortezomib alone or in
combination with other drugs for the treatment of CML and/or
Ph+ALL [7,8]. Thus, bortezomib is a promising treatment in
Bcr-Abl-positive leukemias.
An interesting study suggested that bortezomib in
combination with the cyclin-dependent kinase (CDK) inhibitor
flavopiridol synergizes to induce apoptosis in CML cells [4].
Flavopiridol causes an inhibition of the cell cycle in G1 or G2,
based on the inhibition of CDK [4]. Other studies have shown
that leukemic cells are particularly sensitive when survival
pathway inhibitors are combined with mitotic inhibitors [9].
Moreover, combination of bortezomib with mitotic inhibitors
(such as paclitaxel) are currently in clinical trials for the
treatment of non-small-cell lung carcinoma (NSCLC) and other
solid tumors [10]. Thus, we hypothesized that a strategy based
on the combined treatment with bortezomib and mitotic
inhibitors for the treatment of Bcr-Abl-positive leukemias may
be promising. Especially important might be to determine the
effectiveness of this strategy in TKIs-resistant Bcr-Abl-positive
cases.
Paclitaxel (Taxol), a mitotic inhibitor drug acting by
stabilization of microtubules [11], is FDA approved for the
treatment of lung, ovarian, breast cancers and advanced forms
of Kaposi’s sarcoma. Paclitaxel is now in clinical trials for the
treatment of CML [7,11]. However, to our knowledge, there are
no clinical trials or published studies employing the combined
bortezomib and paclitaxel regimen for the treatment of Bcr-Abl-
positive CML. Such a combination, if synergistic in inducing
apoptosis in Bcr-Abl-positive cells, would significantly decrease
the dose of each compound necessary to achieve a therapeutic
effect.
Here we demonstrate that bortezomib, in combination with
the mitotic inhibitor paclitaxel, efficiently kill TKIs-resistant and -
sensitive Bcr-Abl-positive leukemic cells. In addition,
bortezomib in combination with either paclitaxel or BI 2536,
another mitotic inhibitor that inhibits PLK1, induces a marked
downregulation of total and phosphorylated Bcr-Abl protein
levels, thus downregulating the critical Bcr-Abl downstream
signaling pathways and activating caspases. Similarly,
bortezomib, in combination with other mitotic inhibitors
(vincristine and docetaxel), is able to decrease Bcr-Abl activity
and increase caspase activation. Taken together, our findings
unravel a novel promising treatment for TKIs-resistant and
sensitive CML cases, as well as other Bcr-Abl positive
leukemias.
Materials and Methods
Cell lines and cell culture reagents
K562 and LAMA84 cell lines were purchased from ATCC.
The K562 imatinib-resistant cell lines (K562-R) and LAMA84
imatinib-resistant cell lines (LAMA-R) were generated in our
laboratory, by incubation of the K562 and LAMA84 cells,
respectively, with increasing concentrations of imatinib
mesylate for 3-4 weeks, as described in earlier studies [12].
The K562-R and LAMA84-R cells were then continuously
cultured in 1μM imatinib mesylate for the course of the
experiments.
Baf3 cells containing either the control vector pMSCV,
pMSCV-Bcr-Abl or Baf3 Bcr-Abl T315I cells have been
previously described (see Acknowledgements section for
details).
All cell lines were grown in RPMI 1640 medium (Mediatech
Inc., VA, USA, Cat. # 10-040-CV) supplemented with 10% fetal
bovine serum (FBS, HyClone, Cat. # SH30088.03). 2mM L-
glutamine (Mediatech, VA, USA, Cat. # 25-005-CI) and 100
units/ml Penicillin/ 100 μg/ml Streptomycin (Mediatech Inc., VA,
USA, Cat. # 30-001-CI). Cells were passed every 2-3 days and
used in experiments during their logarithmic growth phase.
Cellular treatments
Bortezomib (also named Velcade, PS-341, Millennium
Pharmaceuticals, Cambridge, MA, USA) and imatinib mesylate
(also named Gleevec, STI-571, Novartis, Basel, Switzerland)
were purchased from the Beth Israel Deaconess Medical
Center Pharmacy (approved for research purposes only). The
sensitivity of K562, K562-R, LAMA84, LAMA84-R, Baf3 Bcr-
Abl, and Baf3 Bcr-Abl T315I cell lines to the most used Bcr-Abl
inhibitors in CML: imatinib, dasatinib (Santa Cruz
Biotechnology, CA, USA, Cat. # sc-218081) and nilotinib
(Santa Cruz Biotechnology, CA, USA, Cat. # sc-202245) was
investigated by treating these cells with increasing
concentrations of each drug and measuring cell death using an
automated Trypan Blue exclusion method (see Figures S2, S3
and S4).
Paclitaxel (Sigma, MO, USA, Cat # T7402), BI 2536 (Selleck
Chemicals, TX, USA, Cat. # S1109), docetaxel (Santa Cruz
Biotechnology, CA, USA, Cat. # sc-201436) and vincristine
(Santa Cruz Biotechnology, CA, USA, Cat. # sc-338734) were
used alone or in combination with bortezomib to evaluate the
effect of bortezomib in combination with diverse mitotic
inhibitors on Bcr-Abl-positive cells (see Figures 1-6 and Figure
S1).
Viability/cell death analysis (automated trypan blue
exclusion assay)
Cell death and viability were measured using an automated
Trypan Blue exclusion assay. The BioRad TC10 automated cell
counter is designed to accurately score Trypan Blue-positive
Combined Regimen for Targeting TKIs-resistant CML
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and -negative suspended cells and can determine viability by
an automated image analysis algorithm. The TC10 counter
demonstrates high reproducibility when cell concentration is
within 5x104 - 107 cells/ml (we used and recommend a
concentration higher than 105 cells/ml) and the cells measure
6-50 μm in diameter. Briefly, after treating the cells with
indicated drugs for the specified time, a volume of 30-40 μl of
cells is mixed with an equal volume of Trypan Blue solution
Figure 1.  Combined treatment of bortezomib and
paclitaxel efficiently activates caspases and induces cell
death in human leukemic Bcr-Abl-positive K562 and
LAMA84 cell lines.  A. K562 leukemic cells were exposed to
bortezomib (9nM) with or without paclitaxel (6nM) for 48h. The
percentage of cell death was measured with an automated
Trypan Blue exclusion method. The combination significantly
increased the number of Trypan Blue-positive cells, compared
with each drug used alone. The results represent the mean +/-
standard deviations (SDs) of 4 measurements/condition for the
representative Western blot experiment presented in (B). B.
K562 leukemic cells were treated with 9nM bortezomib and
6nM paclitaxel for 48h, followed by detection of the cleaved
fragments of caspase 3, and of PARP cleavage. The combined
regimen induced significant cleavage of caspases 3, 8 & 9, and
PARP, implying caspase activation. C. LAMA84 leukemic cells
were exposed to bortezomib (4nM) with or without paclitaxel
(5nM), for 48h. The percentage of cell death was measured
with an automated Trypan Blue exclusion method. The
combination significantly increased the number of Trypan Blue-
positive cells, compared with each drug used alone. The
results represent the mean +/- standard deviations (SDs) of 5
measurements/condition for the representative Western blot
experiment presented in (D). D. LAMA84 leukemic cells were
treated with 4nM bortezomib and 5nM paclitaxel for 48h,
followed by detection of the cleaved fragments of caspase 3,
caspase 8, caspase 9 and of PARP cleavage. The combined
regimen significantly enhanced the cleavage of caspases 3, 8,
9 and PARP, suggesting caspase activation. At least 3
separate experiments were performed in each case. β-Actin
was used as a loading control; “***” = p<0.0001; “**” = p<0.01;.
doi: 10.1371/journal.pone.0077390.g001
(0.4%). 10 μl of this mix is then loaded on a special counting
chamber and measured with the BioRad TC10 cell counter
after 10 seconds. At least six readings were made for each
condition, in each individual experiment. This method was used
for the dose-effect experiments and for demonstrating the
synergistic effect of the bortezomib and paclitaxel combination.
Cell death/apoptosis analysis (PE-Annexin V/7-AAD
staining)
To confirm the results obtained with Trypan blue assay,
K562 cells treated with bortezomib, paclitaxel or the
combination were also evaluated by PE-Annexin V/7-AAD
staining (PE Annexin V Apoptosis Detection Kit I, BD
PharMingen, San Diego, CA) and flow cytometry.
Viability analysis (MTT assay)
Viability/proliferation was measured by using the MTT assay
(MTT kit, Invitrogen), which is a standard colorimetric assay for
measuring the activity of enzymes that reduce MTT to
formazan, giving a purple color. Human leukemic K562 cell
lines were treated with bortezomib, paclitaxel and combination,
using the specified doses, in 96 well plates, at the density of
10,000 cells/well (5 wells were used for each condition) in each
individual experiment. After 24 or 48h, MTT assay was
performed. The absorbance was measured at 570 nm.
Proliferation analysis (BrdU incorporation assay)
Proliferation was measured by using the BD Pharmingen
BrdU Flow Cytometry Kit. Briefly, human leukemic cells K562
were treated with bortezomib, paclitaxel or combination, for
40h. Cells were exposed to BrdU for 90 min before fixation and
permeabilization. Cells were analyzed by flow cytometry for
BrdU incorporation by using an anti-BrdU FITC coupled
antibody, following the manufacturer’s instructions.
Determination of the synergistic effect
The synergistic effect of the combined treatment was
established as previously described [13], by using the Chou
and Talalay method [14]. This is a generalized method for
analyzing the effects of multiple drugs and for determining
summation, synergism and/or antagonism. K562, LAMA84 &
K562-R cells were treated with increasing concentrations from
each drug alone and in combination, maintaining the same
concentration ratio of bortezomib/paclitaxel (1/1.5). The value
of the Combination Index (CI) using Chou-Talalay method that
indicates synergism is CI < 1, while CI = 1 shows an additive
effect and CI > 1, antagonism [14].
Western blot
Suspension cells were washed with PBS and lysed in RIPA
buffer. SDS-PAGE and the immunoblotting were performed as
previously described [15]. Most of the antibodies employed for
probing the Immobilon PVDF membranes were purchased from
Cell Signaling Technology (MA, USA) and used at dilutions of
1:1,000 or 1:1,500: c-Abl (# 2862), P-Bcr Y177 (# 3901), CrkL
32H4 (# 3182), P-CrkL Y207 (# 3181), Lyn (# 2732), P-Lyn
Y507 (# 2731), Stat 5 (# 9363), P-Stat 5 Y694 (# 9359), Stat 3
Combined Regimen for Targeting TKIs-resistant CML
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(# 9132), P-Stat 3 S727 (# 9134), p38 MAPK (# 9212), P-p38
MAPK T180/Y182 (# 4511), SAPK/JNK 56G8 (# 9258), P-
SAPK/JNK T183/Y185 (# 9251), p44/42 MAPK (ERK 1/2) (#
4695), P-p44/42 MAPK T202/Y204 (# 4370), PARP (# 9542),
Caspase 3 (# 9662), Cleaved Caspase3 (# 9664), Caspase 8
1C12 (# 9746), Cleaved Caspase 8 (# 9496), Caspase 9 (#
9502). Anti-β-Actin antibody (clone AC-15) (# A5441) was
purchased from Sigma (MO, USA) and used at a dilution of
1:20,000.
The quantitative analysis of the protein expression levels
(normalized to beta-Actin) was done using ImageJ software,
following the developer’s instructions (the background was
substracted and the image was inverted, to minimalize the
errors).
Photomicrograph and image processing
Phase contrast/bright field microscope images were taken
using a Nikon Eclipse TI-S Inverted Microscope (4x or 10x
objective lenses) and by using QCapture 2.99.5 software
(2009, Quantitative Imaging Corporation).
Statistical analysis
The values presented in the graphs of this manuscript
represent the means +/- SD. Student t test (2 tailed distribution,
unpaired) was employed to analyze the significance of the
differences between experimental variables (“*” = p < 0.05; “**”
= p<0.01; “***” = p<0.0001). See Figure legends for details of
each experiment.
Figure 2.  Cotreatment with bortezomib and paclitaxel induces activation of stress-dependent kinases JNK and p38, but
not of the cytoprotective ERK kinases in K562 and LAMA84 cell lines.  A. K562 leukemic cells were treated with 9nM
bortezomib and 6nM paclitaxel for 48h, followed by detection of the total and phosphorylated protein levels of p38MAPK, JNK 1&2
and ERK 1&2. The combined regimen induced a strong increase in phosphorylation of the p38MAPK and JNK 1&2, and a slight
increase in P-ERK 1&2. B. LAMA84 leukemic cells were treated with 4nM bortezomib and 5nM paclitaxel for 48h, followed by
detection of the total and phosphorylated protein levels of p38MAPK, JNK 1&2 and ERK 1&2. β-Actin was used as a loading control.
One representative experiment from three separate experiments is shown.
doi: 10.1371/journal.pone.0077390.g002
Combined Regimen for Targeting TKIs-resistant CML
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e77390
Results
Combined treatment with bortezomib and paclitaxel
efficiently activates caspases and induces cell death in
human leukemic Bcr-Abl-positive K562 and LAMA84
cell lines
Dose-effect curves for single treatments with bortezomib
[1,4] and paclitaxel [16] were previously determined in K562,
LAMA84 or Baf3 Bcr-Abl cells by us or other groups. To assess
bortezomib/paclitaxel interaction in Bcr-Abl positive cells, K562
and LAMA84 were exposed to 9nM (K562) or 4nM (LAMA84)
bortezomib, alone or in combination with 6nM (K562) or 5nM
(LAMA84) paclitaxel, for 48h. Specifically, 9nM bortezomib in
combination with 6nM paclitaxel induces 48% cell death in
K562, while each treatment alone induces less than 21% cell
death, as measured with Trypan Blue exclusion assay (Figure
1a). The combined treatment results in a decrease in pro-
Figure 3.  Bortezomib and paclitaxel combined treatment
significantly downregulates phosphorylated Bcr-Abl
levels, inhibiting the phosphorylation/activity of
downstream STAT3/STAT5, CrkL and Lyn kinase-
dependent pathways, in K562 & LAMA84 cell lines.  A.
K562 leukemic cells were treated with 9nM bortezomib and
6nM paclitaxel for 48h, followed by detection of the
phosphorylated levels of Bcr-Abl, and of the total and
phosphorylated protein levels of STAT3, STAT5, CrkL and Lyn.
The combined regimen significantly downregulates the
phosphorylation of Bcr-Abl, CrkL and Lyn kinases, the total
levels and phosphorylation of STAT5 and the phosphorylation
of STAT3 transcription factors. B. LAMA84 leukemic cells were
treated with 4nM bortezomib and 5nM paclitaxel for 48h,
followed by detection of the phosphorylated levels of Bcr-Abl,
and of the total and phosphorylated levels of STAT3, STAT5,
CrkL and Lyn. The combined regimen significantly
downregulates the phosphorylation of Bcr-Abl, CrkL and Lyn
kinases, and the total levels and phosphorylation of STAT5. β-
Actin was used as a loading control. One representative
experiment from three separate experiments is shown.
doi: 10.1371/journal.pone.0077390.g003
caspase 3, as well as a significant increase in cleavage of the
initiator caspases 8 and 9 and the effector caspase 3, in K562
cells (Figure 1b). This indicates activation of caspases, and
suggests the involvement of both the extrinsic and intrinsic
pathways of apoptosis. In order to analyze the direct activity of
caspases on their known substrates, we have detected the
Poly(ADP-Ribose) Polymerase (PARP) cleavage by Western
blot. PARP is a well established substrate for many caspases
[17]. PARP cleavage was significantly enhanced in the
combined treatment compared with each treatment alone
underscoring caspase activation during bortezomib/paclitaxel-
induced cell death (Figure 1b, cleaved fragment marked
with“*”). Similarly, LAMA84 cell treated with 4nM bortezomib in
combination with 5nM paclitaxel resulted in 41% cell death,
while single treatments induce 15% (bortezomib) and 19%
(paclitaxel) cell death (Figure 1c). Combined treatment induced
a decrease of pro-caspase 3 and a significant increase in
cleaved fragments of caspases 3, 8, 9. These results correlate
with an increase in PARP cleavage (Figure 1d, cleaved
fragment marked with “*”)
We further confirmed these results by analyzing bortezomib/
paclitaxel-induced cell death/apoptosis with Annexin V/7AAD
and the effect on viability/proliferation with MTT assay, in K562
(Figure S1a and b). Moreover, the effect on proliferation was
also determined. Notably, while in the control and bortezomib
treatments, 90min of BrdU exposure resulted in a BrdU
incorporation of 65.1% and 60.1% cells respectively, in
paclitaxel treated cells and combination the proliferation is
significantly decreased (19.7% and 29.2% respectively).
Combined treatment has less effect on proliferation compared
to paclitaxel alone, suggesting that combined regimen is acting
mainly by inducing cell death, and only partially by inhibiting
proliferation (Figure S1c).
In addition, dose-effect analysis of this caspase-induced cell
death by Trypan Blue exclusion in K562 and LAMA84 cells
revealed a combination index (CI) with values lower than 1,
which shows that bortezomib and paclitaxel act synergistically
in inducing cell death (Figure S2a and b).
Co-treatment with bortezomib and paclitaxel induces
activation of stress-dependent kinases JNK and p38 in
K562 and LAMA84 cell lines
Previous reports have shown that Bcr-Abl and various
treatments (such as imatinib, dasatinib, nilotinib and
bortezomib) are able to modulate the MAPK cascades [3,4]. In
order to evaluate the bortezomib and paclitaxel interactions
with MAPK signaling pathways, we analyzed the effect of
bortezomib and paclitaxel combined treatment on activation
p38MAPK, JNK and ERK. While bortezomib or paclitaxel alone
are able to induce a slight increase in phosphorylated
p38MAPK, combined treatment leads to a robust p38MAPK
activation, with more than 100x increase in K562 and 2x
increase in LAMA84, compared with the control. Similar to
other reports [4], bortezomib alone is able to induce an
increase in JNK phosphorylation (activation) (Figure 2a & b).
JNK activation is further increased when bortezomib is used in
combination with paclitaxel, in both K562 and LAMA84 cell
lines (Figure 2a and b). Treatment with bortezomib, paclitaxel
Combined Regimen for Targeting TKIs-resistant CML
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or their combination did also increase the phosphorylation of
ERK1/2. However, the increase of P-ERK1/2 is modest: 1.31x
in K562 and 1.7x in LAMA84. Notably, when slightly lower
concentrations of bortezomib (7.5-8nM) and paclitaxel (5nM)
are used in K562, the combined treatment does not result in an
increase in P-ERK1/2 (Figure S3a), while levels of P-p38
(Figure S3b) and cleaved caspase 3 (data not shown) are
significantly increased. These findings suggest that the
bortezomib/paclitaxel regimen induces a significant activation
of stress-dependent kinases (JNK & p38 MAPK), while the
cytoprotective kinases ERK1 & ERK2 are only activated at
higher concentrations (Figure 2).
Bortezomib and Paclitaxel combined treatment
significantly downregulates phosphorylated Bcr-Abl
levels, inhibiting the phosphorylation/activity of
downstream STAT3/STAT5, CrkL and Lyn-dependent
pathways (K562 & LAMA84 cell lines)
The combined treatment with bortezomib and paclitaxel
decreases the phosphorylation (activity) of Bcr-Abl in both
K562 and LAMA84 cell lines (Figure 3, right panels). This
intriguing result suggests that the combination targets Bcr-Abl
through a novel mechanism.
Previous reports suggest that Bcr-Abl is able to induce
activation of multiple downstream pathways through
phosphorylation of the CrkL adaptor protein, phosphorylation of
Figure 4.  Bortezomib/paclitaxel combination induces downregulation of the total levels and phosphorylation of Bcr-Abl in
TKIs-resistant K562-R, LAMA84-R and Baf3 Bcr-Abl T315I, displaying increased Bcr-Abl expression/activity and/or T315I
mutation.  A. K562 (K562-S) and K562-R leukemic cells were treated with 9nM bortezomib and 6nM paclitaxel for 48h, followed by
detection of the total levels and phosphorylation of Bcr-Abl. The combined regimen significantly decreases the phosphorylation of
Bcr-Abl in both cell lines. B. LAMA84 (LAMA84-S) and LAMA84-R leukemic cells were treated with 4nM bortezomib and 5nM
paclitaxel for 48h, followed by detection of the total levels and phosphorylation of Bcr-Abl. The combined regimen downregulates the
total levels and phosphorylation of Bcr-Abl in LAMA84-R and phosphorylation of Bcr-Abl in LAMA84-S. C. Baf3 Bcr-Abl and Baf3
Bcr-Abl T315I cell lines were treated with 7nM bortezomib and 7nM paclitaxel for 48h, followed by detection of the total levels and
phosphorylation of Bcr-Abl. The combined regimen decreases the phosphorylation of Bcr-Abl in both cell lines. β-Actin was used as
a loading control. One representative experiment from several separate experiments is shown.
doi: 10.1371/journal.pone.0077390.g004
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the Lyn kinase, and activation of the JAK/STAT pathway by
phosphorylation of STAT proteins [18-20]. Thus, we evaluated
the phosphorylation of these downstream factors. The
combined treatment with bortezomib and paclitaxel clearly
decreases the phosphorylation of CrkL and Lyn, in both K562
and LAMA84 leukemic cell lines (Figure 3). These proteins are
known to be activated by phosphorylation and mediate the
pathways implicated in cell transformation and movement
(CrkL) [18] or cell survival (Lyn) [19]. Additionally, bortezomib
and paclitaxel combination induces the downregulation of total
Figure 5.  Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total
levels and phosphorylation of Bcr-Abl, a decrease of downstream phosphorylated STAT5 and a caspase-dependent cell
death in TKIs-resistant and –sensitive K562 cell lines.  A. K562 leukemic cells were plated in 75cm2 flasks (2 x 106 cells/30 ml/
flask) and treated with 9nM bortezomib, 8nM BI 2536 or the combination, for 60h. Phase contrast microscope images of the
untreated or treated cells are presented. A Nikon Eclipse TI-S Inverted Microscope was used (10X objective lens). While single
treatments did not significantly change the morphology and number of the cells, the combined treatment induced a change in
morphology/shape and a decrease in the number of the cells. B. K562 leukemic cells were plated in 75cm2 flasks (2 x 106 cells/30
ml/flask) and treated with 9nM, 10nM bortezomib, 8nM, 10nM BI 2536 or the combination, for 60h. Viability was measured by
Trypan Blue dye exclusion method, using a TC10 Automated Cell Counter (Biorad, USA). The results represent the mean +/-
standard deviations (SDs) of 6 measurements/condition for the representative Western blot experiment presented in (C) & (D). C.
K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed by detection of the cleaved caspase 3,
caspase 8, caspase 9 and PARP. The combined regimen significantly enhanced this cleavage, suggesting caspase activation in
both K562 and K562-R cell lines. D. K562 and K562-R cells were treated with 9nM bortezomib and 8nM BI 2536 for 60h, followed
by the detection of Bcr-Abl and phosphorylated STAT5. The combined treatment resulted in a marked decrease of the total levels of
Bcr-Abl, which correlates with a decrease in the phosphorylation of the downstream STAT5 protein, in both K562 and K562-R cells.
β-Actin was used as an internal loading control. A total of three independent experiments were performed. “***” = p<0.0001.
doi: 10.1371/journal.pone.0077390.g005
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levels and phosphorylation of STAT5 (K562 & LAMA84 cells)
and of phosphorylation of STAT3 (K562) (Figure 3). STAT
transcription factors act downstream of Bcr-Abl in mediating
proliferation/survival, transformation and anti-apoptotic signals,
through a number of already established apoptotic/cell cycle
related proteins, such as: Bcl-2, Mcl-1, Cyclins or c-Myc
[20,21].
Taken together, we demonstrate that the bortezomib/
paclitaxel combination effectively inhibits the activity of Bcr-Abl
and of its downstream signaling mediators.
Bortezomib/paclitaxel combination induces a
downregulation of the phosphorylation of Bcr-Abl in
TKIs-sensitive (K562, LAMA84, Baf3 Bcr-Abl) and TKIs-
resistant (K562-R, LAMA84-R, Baf3 Bcr-Abl T315I) cell
lines
In order to evaluate if the combined bortezomib/paclitaxel
regimen can efficiently shut down Bcr-Abl and induce cell death
in Bcr-Abl-positive leukemic cell lines that are resistant to
imatinib, we developed two different cell lines derived from
K562 (K562-R) and LAMA84 (LAMA84-R) cell lines, which are
resistant to 1μM imatinib. Additionally, we have used the Baf3
Bcr-Abl T315I cell line, a Baf3 derivative resistant to 1μM
imatinib. Importantly, these three cell lines also demonstrate
increased resistance to dasatinib and nilotinib (Figures S4, 5
and 6).
Figure 6.  Bortezomib in combination with mitotic inhibitors as a new strategy for CML: combination of bortezomib with
other mitotic inhibitors induces downregulation of the Bcr-Abl phosphorylation/total levels and caspase activation in the
K562 cell line.  A. K562 leukemic cells were treated with 9nM bortezomib and 4nM docetaxel for 48h, followed by the detection of
total Bcr-Abl levels, phosphorylated Bcr-Abl, cleaved caspase 3 and PARP. The combined treatment resulted in a marked decrease
of the total levels and phosphorylation of Bcr-Abl. This effect is associated with an increase in cleavage of both caspase 3 and
PARP. B. K562 leukemic cells were treated with 9nM bortezomib and 4nM vincristine for 48h, followed by the detection of total Bcr-
Abl levels, phosphorylated Bcr-Abl, cleaved caspase 3 and PARP. The combined treatment resulted in a significant decrease in the
total levels and phosphorylation of Bcr-Abl compared with individual treatments. This effect is correlated with an increase in
cleavage of both caspase 3 and PARP. β-Actin was used as an internal loading control; “***” = p<0.0001; “*” = p<0.05;.
doi: 10.1371/journal.pone.0077390.g006
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The effects of 9nM bortezomib, 6nM paclitaxel or both drugs
in combination were evaluated in both parental K562 (imatinib-
sensitive) and TKIs-resistant K562-R cells after 48h of
treatment. Similar to K562, K562-R cells are synergistically
killed by bortezomib/paclitaxel regimen, as shown by a CI lower
than 1 (when affected fraction fa> 0.18) (Figure S7). Notably,
combined treatment with bortezomib and paclitaxel strongly
decreases phosphorylation of Bcr-Abl, in both K562 (K562-S)
and K562-R cell lines (Figure 4a).
The effects of 4nM bortezomib, 5nM paclitaxel or both drugs
in combination for 48h were also evaluated in both parental
LAMA84 (imatinib-sensitive) and TKIs-resistant LAMA84-R
cells. Interestingly, the LAMA84-R cells show a significant
increase in total levels and phosphorylation of Bcr-Abl
oncoprotein when compared with parental LAMA84 cells
(LAMA84-S). This suggests that these cells adapted to resist
imatinib, dasatinib and nilotinib treatments through the
upregulation of Bcr-Abl levels and activity. Combined treatment
with bortezomib and paclitaxel was able to downregulate total
levels and phosphorylation of Bcr-Abl in LAMA84-R cell lines
(Figure 4b).
The T315I point mutation in Bcr-Abl is known to confer
resistance to imatinib, dasatinib, nilotinib, and bosutinib [22]. It
is therefore important to test whether the combined treatment
of bortezomib and paclitaxel is also active on cells expressing
Bcr-Abl with the T315I mutation. While 7nM bortezomib and
7nM paclitaxel alone did not significantly affect the total levels
and phosphorylation of Bcr-Abl T315I in the Baf3 Bcr-Abl T315I
cells, the combined treatment was highly effective in
decreasing the total levels and phosphorylation of Bcr-Abl
T315I (Figure 4c). Our results show that bortezomib and
paclitaxel combined treatment is able to target the TKIs-
resistant cell lines with the T315I mutation in Bcr-Abl.
Bortezomib in combination with the PLK1 inhibitor BI
2536 induces a significant downregulation of the total
levels and phosphorylation of Bcr-Abl, a decrease of
downstream phosphorylated STAT5 and caspase-
dependent cell death in imatinib-, dasatinib- and
nilotinib-resistant and -sensitive K562 cell lines
To determine if bortezomib in combination with other known
mitotic inhibitors can result in similar inhibition of Bcr-Abl
activity and downstream signaling, we analyzed the combined
effect of bortezomib with the known PLK1 inhibitor BI 2536.
PLK1 is a well conserved kinase, critical in all phases of the
mitosis [23]. A previous report suggested that BI 2536 has a
growth inhibitory effect on Bcr-Abl-positive cells, which is not
amplified by bortezomib after 16h of co-treatment [23]. Here we
show that while each treatment alone at 9nM or 10nM
bortezomib and 8nM or 10nM BI 2536 does not significantly
induce cell death in K562 as measured by the Trypan Blue
exclusion method, the combined treatment resulted in a
significant decrease in cell number and in the percentage of the
viable cells (Figure 5a and b). In addition, the prolonged (60h)
co-treatment with 9nM bortezomib and 8nM BI 2536 is effective
in cleaving initiator caspases 8, 9, effector caspase 3 and
caspase-substrate PARP, in both K562 and K562-R cells
(Figure 5c). Moreover, the combined treatment also resulted in
an efficient decrease of the total levels of Bcr-Abl, which
correlates with a decrease in the phosphorylation of the
downstream STAT5 protein, in both K562 and K562-R cells
(Figure 5d).
Bortezomib in combination with mitotic inhibitors as a
novel general strategy in CML: combination of
bortezomib with other mitotic inhibitors induces
downregulation of the Bcr-Abl phosphorylation/total
levels and caspase activation in K562
The combined effects of bortezomib with the mitotic inhibitors
docetaxel and vincristine were also tested. Similar to paclitaxel,
docetaxel induces mitotic arrest by stabilizing microtubules
[24]. The effect of 9nM bortezomib alone, 4nM docetaxel alone,
or both drugs in combination for 48h, was evaluated in K562.
The combined treatment resulted in a significant decrease of
total levels and phosphorylation of Bcr-Abl, and in an increase
in caspase 3 cleavage (Figure 6a).
By contrast, vincristine induces mitotic arrest by destabilizing
microtubules [25]. 9nM bortezomib and 4nM vincristine
combination induces a decrease in total levels and
phosphorylated Bcr-Abl, as well as an increase in caspase 3
cleavage, the effects being higher than in singular treatments
(Figure 6b). Moreover, the combinations of bortezomib with
docetaxel or vincristine resulted in a significant and higher
increase in cell death compared with individual treatments
(Figure 6c & 6d).
Discussion
Collectively, our findings indicate that the bortezomib in
combination with four different mitotic inhibitors (paclitaxel,
docetaxel, vincristine and BI2536), that repress mitosis by
different mechanisms (microtubule stabilization, microtubule
destabilization or PLK1 inhibition) [23-25] are able to shut down
Bcr-Abl activity and result in caspase-dependent cell death in
TKIs-resistant (paclitaxel, BI 2536) and -sensitive (paclitaxel,
docetaxel, vincristine, BI 2536) Bcr-Abl-positive cell lines. A
schematic representation of these findings is presented in
Figure 7 [3,6,18-20,26-34].
Our results demonstrate that regimens of bortezomib
combined with mitotic inhibitors (paclitaxel, docetaxel,
vincristine, BI 2536) are associated with Bcr-Abl and/or P-Bcr-
Abl downregulation. Few other agents (Flavopiridol, HDAC
inhibitors and the PLK1 inhibitor BI 2536) [4,23,35] have been
shown to induce a significant Bcr-Abl downregulation when
used in combination with imatinib. Moreover, the pan-CDK
inhibitor flavopiridol [4], the heat shock protein 90 (Hsp90)
antagonist 17-AAG [36] and the histone deacetylase (HDAC)
inhibitor SAHA [35] were previously revealed to induce
apoptosis in combination with bortezomib, an effect associated
with Bcr-Abl downregulation. Although the exact mechanism of
Bcr-Abl downregulation is still unclear, it seems plausible that
the decrease of Bcr-Abl levels and its inactivation contribute, at
least in part, to the caspase-mediated cell death induced by
these combinations, including the bortezomib/mitotic inhibitors
regimens.
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Our results point out that a bortezomib/paclitaxel
combination inhibits STAT3 and STAT5 activation.
Bortezomib/BI 2536 combination similarly results in a decrease
in P-STAT5 levels in K562 cells. As previously shown, Bcr-Abl
phosphorylates and activates STAT3 and STAT5 transcription
factors resulting in cellular survival and proliferation.
Constitutive activation of STAT5 is known to be critical for the
maintenance of chronic myeloid leukemia and STAT3 is also
constitutively active in Bcr-Abl-positive embryonic stem cells
[20,30]. Thus, cell death induced by inhibition of Bcr-Abl with
imatinib in Bcr-Abl-positive cells is at least in part related to the
inhibition of STAT signaling. Additionally, it is known that JAK-
STAT pathway activation contributes to imatinib and nilotinib
resistance in Bcr-Abl-positive progenitors [37,38]. All these
findings suggest that STAT3/STAT5 signaling inhibition plays
Figure 7.  Bortezomib in combination with mitotic inhibitors as a novel strategy for CML: a model of the combined
treatments-induced cell death.  Our results show that bortezomib in combination with several mitotic inhibitors, known to suppress
mitosis through different mechanisms, is able to downregulate total levels and/or phosphorylation of Bcr-Abl at the Tyr 177 site and
to inactivate the Bcr-Abl downstream pathways, mediated by Lyn, CrkL or STAT3/STAT5. These effects are associated with
caspase-mediated cell death. Tyr177 phosphorylation mediates Bcr-Abl downstream signaling by inducing the formation of a Lyn-
Gab2-Bcr-Abl complex, and is required for Bcr-Abl-induced leukemia [26,27]. This binding results in Lyn activation by
phosphorylation [28]. Lyn kinase further regulates survival and responsiveness of CML cells to inhibition of Bcr-Abl kinase [19].
Interestingly, Lyn can also phosphorylate Tyr177 in Bcr-Abl [26], resulting in a potential feedback mechanism. The Gab2-Bcr-Abl
complex is mediated by Grb2 [3] and results in activation of downstream proliferative/survival pathways, such as Ras-ERK and
PI3K-Akt. Gab proteins couple growth factor and cytokine receptors to downstream proteins, resulting in activation of the
downstream pathways Ras-ERK, PI3K-Akt and JAK/STAT pathways [3,29]. Bcr-Abl phosphorylates and activates STAT3 and
STAT5 transcription factors inducing survival and proliferation. Constitutive activation of STAT3/STAT5 is critical for the
maintenance of chronic myeloid leukemia [20,30]. Bcr-Abl also binds the C-terminal Proline-rich region of the adaptor protein CrkL
[30]. Bcr-Abl phosphorylates CrkL, an event needed for Bcr-Abl-induced leukemia. CrkL can enhance cell migration and Bcr-Abl-
mediated leukemogenesis [6,18,31-34].
doi: 10.1371/journal.pone.0077390.g007
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an important role in bortezomib/paclitaxel- or bortezomib/BI
2536-induced cell death, in Bcr-Abl-positive cells.
Several pathways are known to be critical downstream
mediators of the Bcr-Abl pro-survival and pro-leukemogenic
effects. Bcr-Abl is phosphorylated at multiple phosphorylation
sites, resulting in binding/phosphorylation of downstream Bcr-
Abl mediators. Phosphorylation of Tyrosine 177 induces the
formation of a Lyn - Gab2 - Bcr-Abl complex, important in Bcr-
Abl-induced tumorigenesis [26,27]. Lyn tyrosine kinase binding
to phosphorylated and active Bcr-Abl leads to Lyn activation by
phosphorylation [28]. Lyn further regulates survival and
responsiveness of CML cells to inhibition of Bcr-Abl kinase
[19]. Interestingly, Lyn kinase can also phosphorylate Bcr-Abl
[26], resulting in a potential feedback mechanism. Additionally,
Bcr-Abl phosphorylates CrkL adaptor protein, an event needed
for Bcr-Abl-induced leukemia. CrkL can enhance cell migration
and Bcr-Abl-mediated leukemogenesis [18,31-34]. Thus, Lyn
and CrkL are key regulators and downstream mediators of Bcr-
Abl-induced survival and leukemogenesis that can be inhibited
by downregulation or inhibition of Bcr-Abl. Our results
demonstrate that the combined treatment with bortezomib and
paclitaxel is able to inhibit the activity of these important Bcr-
Abl downstream mediators.
JNK activation was previously associated with apoptosis
induced by bortezomib in Bcr-Abl-positive cells [39] and by
bortezomib in combination with the pan-CDK inhibitor
Flavopiridol in both Bcr-Abl-positive and negative leukemic
cells [4]. In addition, several other studies pointed out the role
of JNK activation in cell death of Bcr-Abl-positive or -negative
cells [40,41]. Thus, the activation of JNK seen in our results
following bortezomib/paclitaxel treatment in Bcr-Abl-positive
cells may contribute to cell death.
Current inhibitors of Abl kinases, such as imatinib, dasatinib
or nilotinib, have shown good results in CML treatment.
However, the emergence of resistance and residual disease
can eventually lead to progression of CML despite treatments
[3,42]. Imatinib, dasatinib or nilotinib resistance may emerge
through point mutations in Bcr-Abl (such as T315I), Bcr-Abl
gene amplification and/or an increase in Bcr-Abl protein levels
[4]. To investigate alternative treatments for these particular
cases, we have indeed developed two different cell lines
derived from K562 (K562-R) and LAMA84 (LAMA84-R) cell
lines, which are completely resistant to 1μM imatinib. While the
levels of Bcr-Abl and P-Bcr-Abl in LAMA84-R are much higher
than in LAMA84-S cells, the levels of Bcr-Abl and P-Bcr-Abl in
K562-R compared with K562-S are much closer to each other
(Figure 4). Thus, the increased expression of Bcr-Abl is
probably at least in part responsible for the LAMA-R resistance
to imatinib, dasatinib and nilotinib, while possible mutations
may be responsible for the K562-R resistance. Additionally, we
have used the Baf3 Bcr-Abl T315I cell line, derived from Baf3
(an immortalized murine pro-B cell line), which is also resistant
to 1μM imatinib and at least partially resistant to dasatinib and
nilotinib treatments (Figures S4-6). In addition to its effect on
imatinib-sensitive cell lines, the bortezomib/paclitaxel regimen
was able to induce caspase cleavage, a measure of caspase
activation [43-45], in K562-R cells and significant
downregulation of the total levels and phosphorylation of Bcr-
Abl in all tested TKIs-resistant cell lines. Thus, such
combination may be a good strategy to treat resistant cases
due to either an increase in Bcr-Abl expression or Bcr-Abl
mutations that abrogate imatinib, dasatinib or nilotinib inhibitory
effects.
Notably, in addition to the bortezomib/paclitaxel regimen, our
results demonstrate that bortezomib, in combination with other
mitotic inhibitors that act by inducing mitotic arrest through
various mechanisms (microtubule stabilization: docetaxel,
microtubule destabilization: vincristine and PLK1 inhibition: BI
2536), inhibits Bcr-Abl and results in caspase 3 activation. It
has previously been established that inhibition of Bcr-Abl
(Imatinib [23]) or knock-down of Bcr-Abl (shRNA for Bcr-Abl
[46]) induces caspase activation and apoptosis. Thus, our
results indicate that Bcr-Abl down-modulation contributes, at
least in part, to caspase activation and induction of cell death.
Both docetaxel and vincristine are FDA-approved for the
treatment of several malignancies, alone or in combination
[47,48]. Interestingly, a recent study concluded that BI 2536
has growth inhibitory effects on Bcr-Abl-positive cells that are
not amplified by bortezomib after 16h of co-treatment [23]. In
contrast, we are showing here that the combined treatment of
bortezomib 9nM with BI 2536 8nM for 60h is significantly more
effective in inducing caspase activation, PARP cleavage and
cell death compared with single treatments, in both K562 and
K562-R cells (Figure 5). The longer time needed for bortezomib
to amplify the effects of BI 2536 might be explained by the
involvement of transcriptional mechanisms in bortezomib/BI
2536-induced cell death, although further experiments are
needed to clarify this aspect.
Recently, two other drugs were approved by FDA for the
treatment of patients with CML whose tumors are resistant to
or who cannot tolerate Imatinib, Dasatinib or Nilotinib therapies:
bosulif (bosutinib) and synribo (omacetaxine mepesuccinate)
[49]. Bosutinib, approved on September 4, 2012, is a TKI
inhibitor efficient against many Bcr-Abl mutations, except T315I
[49,50]. Omacetaxine mepesuccinate, approved on October
26, 2012, is a non-TKI drug intended to be used when
leukemia progresses after therapy with at least two TKIs
[49,51]. While the drug can be used for the treatment of CML
patients with T315I mutation, it shows significant hematologic
toxicity (grade 3-4) in clinical trials: thrombocytopenia (76% of
cases), neutropenia (44% of cases), and anemia (39% of
cases) [49,51]. While these two new approved drugs offer an
option for many patients with imatinib, dasatinib and nilotinib-
resistant CML, novel better strategies have to be developed. In
contrast with bosutinib, our combined treatment with
bortezomib and mitotic inhibitors is able to target Bcr-Abl with
T315I mutation. Moreover, lower concentrations of each drug
can be used in synergistic combinations, which may reduce
toxicity. However, the toxicity of our regimens remains to be
established.
The potential of Bortezomib or Bortezomib-based
combination therapies in hematological malignancies is also
underscored by their ability to target tumor environment
[52,53]. Tumor microenvironment is a dominant force in
inducing resistance to therapy in multiple malignancies [54].
Tumor microenvironment plays a key role in leukemic stem cell
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maintenance [55] and in modulating signal transduction and
resistance in CML [55] and AML [56].
In conclusion, the combination of bortezomib and mitotic
inhibitors such as paclitaxel, docetaxel, vincristine or BI 2536 is
an effective strategy for targeting of both TKIs -resistant and -
sensitive Bcr-Abl-positive leukemic cells. These regimens are
able to inhibit Bcr-Abl activity and its downstream signaling,
and to activate caspase-dependent cell death. In addition,
these regimens are able to overcome the resistance to
imatinib, dasatinib and nilotinib, brought about by Bcr-Abl
protein overexpression or Bcr-Abl mutations (including T315I),
making them attractive potential therapies for Bcr-Abl-positive
leukemias such as CML, especially for those resistant to
current treatments. As the combined treatment is also efficient
in non-CML Bcr-Abl positive cells such as the Baf3 Bcr-Abl cell
line, it may also be a promising therapy for non-CML Ph+
leukemias (Ph+ALL, Ph+AML).
Supporting Information
Figure S1.  Combined treatment of bortezomib and
paclitaxel induces cell death in human leukemic Bcr-Abl-
positive K562 cell line (in support of Figure 1a and b). A.
K562 leukemic cells were exposed to bortezomib (9nM) with or
without paclitaxel (6nM) for 48h. The percentage of cell death
was measured using PE-Annexin V/7-AAD staining and flow
cytometry as described in “Materials and Methods”. A
representative experiment from three individual experiments is
shown here. B. K562 leukemic cells were exposed to
bortezomib (10nM), paclitaxel (5nM) or the combination for
48h. Viability was measured using the MTT assay as described
in “Materials and Methods”. The results represent the mean +/-
standard deviations (SDs) of a representative experiment. “***”
= p<0.0001. C. K562 cells were treated with bortezomib (9nM),
paclitaxel (6nM) or the combination, for 40h. The percentage of
proliferating cells was measured by BrdU incorporation assay
(cells were exposed to BrdU for 90 min before fixation and
permeabilization), as described in “Materials and Methods”
section. A representative experiment from three individual
experiments is shown here.
(TIF)
Figure S2.  Bortezomib and paclitaxel synergistically
induce cell death in K562 (a) and LAMA84 (b) Bcr-Abl
leukemic cells (in support of Figure 1). A. K562 cells were
treated with increasing concentrations of each drug alone and
in combination, maintaining the same concentration ratio of
bortezomib : paclitaxel 1.6 : 1. Calculated Combination Index
(CI) using the Chou-Talalay method is below 1 when the
affected fraction fa>0.1=10%, which demonstrates the
synergism of the combined bortezomib/paclitaxel treatment. A
representation of the calculated CI for a range of affected
fractions from 0.1 to 0.8 is shown. B. LAMA84 cells were
treated with increasing concentrations of each drug alone and
in combination, maintaining the same concentration ratio of
bortezomib: paclitaxel 1: 1.5. The calculated Combination
Index (CI) using the Chou-Talalay method is below 1, which
demonstrates the synergism of the combined bortezomib/
paclitaxel treatment. A representation of the calculated CI for a
range of affected fractions from 0.1 to 1 is shown.
(TIF)
Figure S3.  Combined treatment with 8nM bortezomib and
5 nM paclitaxel induces activation of p38, but not of EKR
(in support of Figure 2). K562 leukemic cells were treated
with 9nM bortezomib and 6nM paclitaxel for 48h, followed by
detection of the total and phosphorylated protein levels of
p38MAPK and ERK 1&2. The combined regimen does induces
a change in phosphorylation of the P-ERK 1&2 (A), but results
in a strong increase in p38 phosphorylation (B). β-Actin was
used as a loading control.
(TIF)
Figure S4.  K562-R cells are resistant to imatinib, nilotinib
and dasatinib treatments (in support of Figures 4a and 5).
K562 (K562-S) and imatinib-resistant K562-R cells were plated
in 25cm2 flasks (0.6-0.8 x 106 cells/10 ml/flask) and treated with
0.5 µM imatinib (Imat), 0.9 µM imatinib, 0.125 µM nilotinib
(Nilot) or 0.0025 µM dasatinib (Dasat) for 48h. Viability was
measured by Trypan Blue dye exclusion method, using a TC10
Automated Cell Counter (Biorad, USA). Results represent the
mean +/- SDs of 6 measurements/condition for the
representative experiment presented in Figure 4a. A total of
three independent experiments were performed; “***” =
p<0.0001; .
(TIF)
Figure S5.  LAMA84-R cells are resistant to imatinib,
nilotinib, dasatinib treatments (in support of Figure 4b).
LAMA84 (LAMA84-S) and imatinib-resistant LAMA84-R cells
were plated in 25cm2 flasks (0.7 x 106 cells/10 ml/flask) and
treated with 0.9 µM imatinib, 0.125 µM nilotinib or 0.005 µM
dasatinib for 48h. Viability was measured by Trypan Blue dye
exclusion method, using a TC10 Automated Cell Counter
(Biorad, USA). Results represent the mean +/- SDs of 8
measurements/condition for the representative experiment
presented in Figure 4b. A total of three independent
experiments were performed; “***” = p<0.0001;.
(TIF)
Figure S6.  Baf3 Bcr-Abl T315 cells are resistant to
imatinib, nilotinib, dasatinib treatments (in support of
Figure 4c). Murine Baf3 Bcr-Abl and Baf3 Bcr-Abl T315I cells
were plated in 75cm2 flasks (4 x 106 cells/35 ml/flask) and
treated with 0.5 or 1 µM imatinib. For nilotinib and dasatinib
treatments, the cells were plated in 25cm2 flasks (2 x 106
cells/10 ml/flask) and treated with 0.125 µM or 0.5 µM nilotinib
and 0.056 µM or 0.112 µM dasatinib for 48h. Viability was
measured by Trypan Blue dye exclusion method, using a TC10
Automated Cell Counter (Biorad, USA). Results represent the
mean +/- SDs of 6 measurements/condition for the
representative experiment presented in Figure 4c. A total of
three independent experiments were performed; “***” =
p<0.0001; .
(TIF)
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Figure S7.  Bortezomib and paclitaxel synergistically
induce cell death in K562-R cells. K562-R cells were treated
with increasing concentrations of each drug alone and in
combination, maintaining the same concentration ratio of
bortezomib : paclitaxel 1.5 : 1. Calculated Combination Index
(CI) using the Chou-Talalay method is below 1 when the
affected fraction fa>0.2=10%, which demonstrates the
synergism of the combined bortezomib/paclitaxel treatment. A
representation of the calculated CI for a range of affected
fractions from 0.1 to 0.9 is shown.
(TIF)
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